Chordate Medical Holding AB (publ) announced that the first patient has been included in the company's open pilot study PM009. The study aims to evaluate the effectiveness of Ozilia in the preventive treatment of patients with chronic migraine who do not respond to treatment with CGRP inhibitors and other migraine medications. PM009 is being conducted at King's College in London with three to four referring clinics and Dr. Jan Hoffmann as the responsible principal investigator.

The goal is to include 25-30 patients in the study.